{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-108448","form_type":"8-K","ticker":"CADL","cik":"0001841387","company_name":"Candel Therapeutics, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.300571+00:00","generated_at":"2026-05-17T13:25:45.595516+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Candel Q2 net loss $4.8M vs $22.2M loss a year ago; positive phase 3 CAN-2409 results in prostate cancer","bullets":["Net loss of $4.8M in Q2 2025 vs $22.2M loss in Q2 2024; net other income of $6.4M due to change in warrant liability fair value.","Phase 3 CAN-2409 in localized prostate cancer met primary endpoint with 30% improvement in DFS (HR 0.70, p=0.0155); RMAT designation received.","BLA submission for CAN-2409 in prostate cancer expected in Q4 2026; cash $100.7M sufficient into Q1 2027.","Appointed Charles Schoch as CFO and Maha Radhakrishnan to Board; completed $15M registered direct offering.","Positive overall survival data from phase 2a CAN-2409 in NSCLC (mOS 24.5 months) and pancreatic cancer (mOS 31.4 months)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-108448","json":"https://secwatch.observer/filing/0000950170-25-108448.json","markdown":"https://secwatch.observer/filing/0000950170-25-108448.md","text":"https://secwatch.observer/filing/0000950170-25-108448.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025108448/0000950170-25-108448-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841387/000095017025108448/cadl-20250814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:25:45.595516+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}